Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
The combination of genetic modification and hematopoietic stem cell (HSC) transplantation may provide the necessary means to develop an alternative treatment option to conventional antiretroviral therapy. As HSCs give rise to all hematopoietic cell types susceptible to HIV infection, modification of...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-11-01
|
Series: | Viruses |
Subjects: | |
Online Access: | http://www.mdpi.com/1999-4915/5/12/2946 |
id |
doaj-1751de6fc77942ac97e2987990d8b7f8 |
---|---|
record_format |
Article |
spelling |
doaj-1751de6fc77942ac97e2987990d8b7f82020-11-24T21:54:35ZengMDPI AGViruses1999-49152013-11-015122946296210.3390/v5122946v5122946Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDSPatrick Younan0John Kowalski1Hans-Peter Kiem2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USAClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USAThe combination of genetic modification and hematopoietic stem cell (HSC) transplantation may provide the necessary means to develop an alternative treatment option to conventional antiretroviral therapy. As HSCs give rise to all hematopoietic cell types susceptible to HIV infection, modification of HSCs is an ideal strategy for the development of infection-resistant immune cell populations. Although promising results have been obtained in multiple animal models, additional evidence is needed to convincingly demonstrate the feasibility of this approach as a treatment of HIV-1 infected patients. Here, we review the potential of HSC transplantation and the recently identified limitations of this approach. Using the Berlin Patient as a model for a functional cure, we contrast the confines of autologous versus allogeneic transplantation. Finally, we suggest that although autologous, gene-modified HSC-transplantation may significantly reduce plasma viremia, reaching the lower detection limits currently obtainable through daily HAART will remain a challenging endeavor that will require innovative combinatorial therapies.http://www.mdpi.com/1999-4915/5/12/2946HIV/AIDSGene TherapyStem Cell Transplantation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Patrick Younan John Kowalski Hans-Peter Kiem |
spellingShingle |
Patrick Younan John Kowalski Hans-Peter Kiem Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS Viruses HIV/AIDS Gene Therapy Stem Cell Transplantation |
author_facet |
Patrick Younan John Kowalski Hans-Peter Kiem |
author_sort |
Patrick Younan |
title |
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS |
title_short |
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS |
title_full |
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS |
title_fullStr |
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS |
title_full_unstemmed |
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS |
title_sort |
genetic modification of hematopoietic stem cells as a therapy for hiv/aids |
publisher |
MDPI AG |
series |
Viruses |
issn |
1999-4915 |
publishDate |
2013-11-01 |
description |
The combination of genetic modification and hematopoietic stem cell (HSC) transplantation may provide the necessary means to develop an alternative treatment option to conventional antiretroviral therapy. As HSCs give rise to all hematopoietic cell types susceptible to HIV infection, modification of HSCs is an ideal strategy for the development of infection-resistant immune cell populations. Although promising results have been obtained in multiple animal models, additional evidence is needed to convincingly demonstrate the feasibility of this approach as a treatment of HIV-1 infected patients. Here, we review the potential of HSC transplantation and the recently identified limitations of this approach. Using the Berlin Patient as a model for a functional cure, we contrast the confines of autologous versus allogeneic transplantation. Finally, we suggest that although autologous, gene-modified HSC-transplantation may significantly reduce plasma viremia, reaching the lower detection limits currently obtainable through daily HAART will remain a challenging endeavor that will require innovative combinatorial therapies. |
topic |
HIV/AIDS Gene Therapy Stem Cell Transplantation |
url |
http://www.mdpi.com/1999-4915/5/12/2946 |
work_keys_str_mv |
AT patrickyounan geneticmodificationofhematopoieticstemcellsasatherapyforhivaids AT johnkowalski geneticmodificationofhematopoieticstemcellsasatherapyforhivaids AT hanspeterkiem geneticmodificationofhematopoieticstemcellsasatherapyforhivaids |
_version_ |
1725867129021923328 |